Eli Lilly and Company Book Value | LLY

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Eli Lilly and Company

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
112 B	78.7 B	64 B	49.5 B	48.8 B	46.6 B	2.7 B	10.9 B	11.7 B	14.1 B	14.6 B	15.4 B	17.6 B	14.8 B	13.5 B	31 B	27.5 B	29.2 B	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
112 B	2.7 B	33.5 B

Quarterly Book Value Eli Lilly and Company

2026-Q2	2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1	2010-Q3	2010-Q2	2010-Q1	2009-Q3	2009-Q2
142 B	117 B	115 B	101 B	89.4 B	75.6 B	71.9 B	63.9 B	57.9 B	54.8 B	53.2 B	49.5 B	47.5 B	-	46.9 B	48.8 B	48.2 B	47.8 B	46.8 B	46.6 B	46.6 B	46.6 B	46.6 B	39.3 B	39.3 B	39.3 B	39.3 B	43.9 B	43.9 B	43.9 B	43.9 B	45 B	45 B	45 B	45 B	38.8 B	38.8 B	38.8 B	38.8 B	35.6 B	35.6 B	35.6 B	35.6 B	36.3 B	37.1 B	37.1 B	37.2 B	35.2 B	35.2 B	35.2 B	35.2 B	34.4 B	34.4 B	34.4 B	34.4 B	33.7 B	33.7 B	33.7 B	33.7 B	29.9 B	27.7 B	27.2 B	27.1 B	26.9 B

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
142 B	26.9 B	47.2 B

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
Aclaris Therapeutics ACRS	103 M	$ 5.32	0.09 %	$ 652 M	USA
ADC Therapeutics SA ADCT	-186 M	$ 1.05	0.46 %	$ 133 M	Schweiz
Agenus AGEN	227 M	$ 7.21	0.7 %	$ 214 M	USA
Фармсинтез LIFE	29.8 B	-	-	-	Russia
Akebia Therapeutics AKBA	32.6 M	$ 0.92	1.64 %	$ 237 M	USA
Alector ALEC	30.6 M	$ 1.93	0.81 %	$ 199 M	USA
Amryt Pharma plc AMYT	357 M	-	-	$ 621 M	Britain
Aligos Therapeutics ALGS	53.5 M	$ 5.05	1.2 %	$ 49.9 M	USA
Alkermes plc ALKS	1.82 B	$ 46.07	0.09 %	$ 7.59 B	Irlanda
Allogene Therapeutics ALLO	293 M	$ 1.69	0.58 %	$ 373 M	USA
Alnylam Pharmaceuticals ALNY	789 M	$ 239.36	0.46 %	$ 31.4 B	USA
Altimmune ALT	225 M	$ 3.24	0.31 %	$ 285 M	USA
ALX Oncology Holdings ALXO	26 M	$ 1.76	0.53 %	$ 94.4 M	USA
Evelo Biosciences EVLO	-4.99 M	-	-14.46 %	$ 27.9 M	USA
Amphastar Pharmaceuticals AMPH	789 M	$ 23.95	1.31 %	$ 1.12 B	USA
AnaptysBio ANAB	364 M	$ 54.31	0.15 %	$ 1.56 B	USA
Anika Therapeutics ANIK	190 M	$ 20.84	0.24 %	$ 299 M	USA
ANI Pharmaceuticals ANIP	541 M	$ 73.59	2.05 %	$ 1.48 B	USA
Aptevo Therapeutics APVO	17.4 M	$ 1.72	0.58 %	$ 543 K	USA
Allakos ALLK	78.8 M	-	-	$ 28.6 M	USA
Aquestive Therapeutics AQST	-33.7 M	$ 4.82	0.21 %	$ 515 M	USA
Arcturus Therapeutics Holdings ARCT	214 M	$ 15.6	0.25 %	$ 427 M	Israel
Armata Pharmaceuticals ARMP	-219 M	$ 4.07	2.21 %	$ 147 M	USA
Assembly Biosciences ASMB	207 M	$ 25.48	0.54 %	$ 286 M	USA
Actinium Pharmaceuticals ATNM	7.83 M	$ 1.24	0.79 %	$ 38.7 M	USA
AbbVie ABBV	134 B	$ 262.51	0.01 %	$ 464 B	USA
Atara Biotherapeutics ATRA	-38.5 M	$ 10.11	7.1 %	$ 127 M	USA
Aurinia Pharmaceuticals AUPH	581 M	$ 16.96	5.15 %	$ 2.28 B	Canada
Autolus Therapeutics plc AUTL	178 M	$ 1.87	0.53 %	$ 498 M	Britain
Atea Pharmaceuticals AVIR	275 M	$ 5.15	1.24 %	$ 420 M	USA
Axon Enterprise AXON	3.24 B	$ 468.42	5.96 %	$ 36.6 B	USA
Axsome Therapeutics AXSM	88.3 M	$ 211.97	3.87 %	$ 10.5 B	USA
Aytu BioScience AYTU	124 M	$ 1.97	0.5 %	$ 12.4 M	USA
BridgeBio Pharma BBIO	-2.08 B	$ 68.3	0.1 %	$ 13.1 B	USA
Bicycle Therapeutics plc BCYC	610 M	$ 3.64	0.68 %	$ 252 M	Britain
Black Diamond Therapeutics BDTX	112 M	$ 1.94	1.02 %	$ 110 M	USA
Beam Therapeutics BEAM	1.24 B	$ 23.1	0.15 %	$ 2.28 B	USA
Biogen BIIB	18.3 B	$ 216.01	0.42 %	$ 31.6 B	USA
BioLineRx Ltd. BLRX	23.3 M	$ 2.48	0.79 %	$ 6.11 B	Israel
AbCellera Biologics ABCL	967 M	$ 11.67	2.28 %	$ 3.49 B	Canada
Benitec Biopharma BNTC	177 M	$ 11.04	0.9 %	$ 514 M	USA
Checkmate Pharmaceuticals CMPI	69.5 M	-	-	$ 231 M	USA
Burford Capital Limited BUR	3.13 B	$ 3.87	0.8 %	$ 848 M	Britain
Clovis Oncology CLVS	-279 M	-	-7.23 %	$ 13 M	USA
Chimerix CMRX	122 M	-	-	$ 756 M	USA
Concert Pharmaceuticals CNCE	112 M	-	-	$ 401 M	USA
Cabaletta Bio CABA	112 M	$ 2.49	0.39 %	$ 250 M	USA
Can-Fite BioPharma Ltd. CANF	9.51 M	$ 2.24	0.89 %	$ 3.69 M	Israel
Catalyst Biosciences CBIO	142 M	$ 17.18	1.7 %	$ 1.53 B	USA
C4 Therapeutics CCCC	257 M	$ 3.45	0.58 %	$ 286 M	USA